(PCT) Purecycle Technologies - Overview
Sector: Industrials | Industry: Pollution & Treatment Controls | Exchange: NASDAQ (USA) | Market Cap: 2.047m USD | Total Return: 18.6% in 12m
Avg Turnover: 48.4M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Interest Coverage Ratio -2.8 is critical
Beneish M-Score -1.09 > -1.5 - likely earnings manipulation
Altman Z'' -5.16 < 1.0 - financial distress zone
Tailwinds
No distinct edge detected
PureCycle Technologies (PCT) specializes in the production of ultra-pure recycled polypropylene (PP) using a proprietary physical separation process. This technology removes contaminants, colors, and odors from waste plastic to create a resin suitable for high-grade consumer packaging and industrial applications. As a member of the commodity chemicals sub-industry, the company operates in a sector increasingly driven by corporate sustainability mandates and regulatory pressure to reduce virgin plastic consumption.
Polypropylene is one of the most widely used polymers globally, yet it historically maintains lower recycling rates compared to PET or HDPE due to degradation during traditional mechanical processing. PureCycles license-based model aims to address this gap by restoring waste material to near-virgin quality without chemical decomposition. Investors can evaluate the long-term scalability of this purification technology by reviewing the detailed financial projections available on ValueRay.
Headquartered in Orlando, Florida, PureCycle transitioned to the public markets in 2020. The company’s growth strategy centers on scaling its production facilities to meet the rising demand for circular economy solutions within the global Materials sector.
- Ironton facility production ramp-up validates commercial scale and reliability
- Feedstock procurement costs and purity impact gross processing margins
- Regulatory mandates for recycled content drive premium pricing demand
- Strategic capital allocation and liquidity management support global plant expansion
| Net Income: -224.8m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.20 > 0.02 and ΔFCF/TA 5.66 > 1.0 |
| NWC/Revenue: 557.9% < 20% (prev -246.2%; Δ 804.1% < -1%) |
| CFO/TA -0.17 > 3% & CFO -146.5m > Net Income -224.8m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.71 > 1.5 & < 3 |
| Outstanding Shares: last quarter (180.5m) vs 12m ago 1.10% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 1.30% > 50% (prev 2.11%; Δ -0.81% > 0%) |
| Interest Coverage Ratio: -2.82 > 6 (EBITDA TTM -150.2m / Interest Expense TTM 64.8m) |
| A: 0.07 (Total Current Assets 146.4m - Total Current Liabilities 85.6m) / Total Assets 886.0m |
| B: -0.96 (Retained Earnings -849.4m / Total Assets 886.0m) |
| C: -0.22 (EBIT TTM -182.8m / Avg Total Assets 836.7m) |
| D: -0.97 (Book Value of Equity -849.8m / Total Liabilities 878.6m) |
| Altman-Z'' = -5.16 = D |
| DSRI: 3.91 (Receivables 3.83m/1.49m, Revenue 10.9m/16.6m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.81 (AQ_t 0.01 / AQ_t-1 0.02) |
| SGI: 0.66 (Revenue 10.9m / 16.6m) |
| TATA: -0.09 (NI -224.8m - CFO -146.5m) / TA 886.0m) |
| Beneish M = -1.09 (Cap -4..+1) = D |
As of May 27, 2026, the stock is trading at USD 12.27 with a total of 6,032,175 shares traded.
Over the past week, the price has changed by -4.36%,
over one month by +68.54%,
over three months by +51.11% and
over the past year by +18.55%.
Purecycle Technologies has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PCT.
- StrongBuy: 2
- Buy: 0
- Hold: 2
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 11.8 | -3.6% |
P/E Forward = 142.8571
P/S = 187.7981
P/B = 275.6561
Revenue TTM = 10.9m USD
EBIT TTM = -182.8m USD
EBITDA TTM = -150.2m USD
Long Term Debt = 353.3m USD (from longTermDebt, last quarter)
Short Term Debt = 11.0m USD (from shortTermDebt, last quarter)
Debt = 807.8m USD (from shortLongTermDebtTotal, last quarter) + Leases 68.9m
Net Debt = 686.2m USD (calculated: Debt 807.8m - CCE 121.6m)
Enterprise Value = 2.73b USD (2.05b + Debt 807.8m - CCE 121.6m)
Interest Coverage Ratio = -2.82 (Ebit TTM -182.8m / Interest Expense TTM 64.8m)
EV/FCF = -15.55x (Enterprise Value 2.73b / FCF TTM -175.8m)
FCF Yield = -6.43% (FCF TTM -175.8m / Enterprise Value 2.73b)
FCF Margin = -1.61k% (FCF TTM -175.8m / Revenue TTM 10.9m)
Net Margin = -2.06k% (Net Income TTM -224.8m / Revenue TTM 10.9m)
Gross Margin = unknown ((Revenue TTM 10.9m - Cost of Revenue TTM 151.9m) / Revenue TTM)
Tobins Q-Ratio = 3.09 (Enterprise Value 2.73b / Total Assets 886.0m)
Interest Expense / Debt = 8.02% (Interest Expense 64.8m / Debt 807.8m)
Taxrate = 21.0% (US default 21%)
NOPAT = -144.4m (EBIT -182.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.71 (Total Current Assets 146.4m / Total Current Liabilities 85.6m)
Debt / Equity = 108.8 (Debt 807.8m / totalStockholderEquity, last quarter 7.42m)
Debt / EBITDA = -4.57 (negative EBITDA) (Net Debt 686.2m / EBITDA -150.2m)
Debt / FCF = -3.90 (negative FCF - burning cash) (Net Debt 686.2m / FCF TTM -175.8m)
Total Stockholder Equity = 55.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -26.87% (Net Income -224.8m / Total Assets 886.0m)
RoE = -24.86% (Net Income TTM -224.8m / Total Stockholder Equity 904.5m)
RoCE = -14.54% (EBIT -182.8m / Capital Employed (Equity 904.5m + L.T.Debt 353.3m))
RoIC = -18.65% (negative operating profit) (NOPAT -144.4m / Invested Capital 774.7m)
WACC = 12.74% (E(2.05b)/V(2.86b) * Re(15.27%) + D(807.8m)/V(2.86b) * Rd(8.02%) * (1-Tc(0.21)))
Discount Rate = 15.27% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 73.33 | Cagr: 4.31%
[DCF] Fair Price = unknown (Cash Flow -175.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.02 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.28 | Chg30d=-20.21% | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=-0.26 | Chg30d=-17.05% | Revisions=-20% | Analysts=4
EPS current Year (2026-12-31): EPS=-1.00 | Chg30d=-8.67% | Revisions=-20% | GrowthEPS=-1.5% | GrowthRev=+363.7%
EPS next Year (2027-12-31): EPS=-0.80 | Chg30d=-7.41% | Revisions=-20% | GrowthEPS=+20.4% | GrowthRev=+200.8%
[Analyst] Revisions Ratio: -20%